13F portfolio / Healthcare specialist
Deerfield Company
Deerfield Management is a New York City investment firm that focuses on healthcare.
- Reported 13F value
- $9.6B
- Positions
- 82
- Est. 1-yearEstimate
- —SPY +15.7%
- Est. 3-year, annualizedEstimate
- —SPY +22.8%
As of Jun 30, 2026 · filed Aug 14, 2026
Holdings
13 new · 13 added · 12 trimmed · 44 unchanged · 13 sold out
| 1 | — | Nuvalent IncCOM | 22.2% | $2.1B | 17,248,450 | Unchanged | — | — | — |
| 2 | — | Brookdale Sr Living IncNOTE 3.500%10/1 | 6.1% | $586M | 306,885,000 prn | Unchanged | — | — | — |
| 3 | RVMD on Yahoo Finance (opens in a new tab) | Revolution Medicines IncCOM | 4.7% | $448M | 2,392,000 | Added +4.1% | $35.98* | $177.00 | +391.9% |
| 4 | PRAX on Yahoo Finance (opens in a new tab) | Praxis Precision Medicines ICOM NEW | 3.4% | $323M | 963,351 | Unchanged | $81.93 | $244.24 | +198.1% |
| 5 | VTRS on Yahoo Finance (opens in a new tab) | Viatris IncCOM | 3.3% | $321M | 20,206,170 | Unchanged | $9.08* | $18.32 | +101.9% |
| 6 | CNC on Yahoo Finance (opens in a new tab) | Centene Corp DelCOM | 3.3% | $315M | 4,901,000 | Trimmed -17.2% | $43.36* | $69.22 | +59.7% |
| 7 | — | Revolution Medicines IncNOTE 0.500% 5/0 | 2.6% | $252M | 200,000,000 prn | New | — | — | — |
| 8 | UTHR on Yahoo Finance (opens in a new tab) | United Therapeutics Corp DelCOM | 2.6% | $248M | 457,000 | Unchanged | $333.18 | $531.44 | +59.5% |
| 9 | — | Arrowhead Pharmaceuticals InNOTE 1/1 | 2.5% | $241M | 200,000,000 prn | Unchanged | — | — | — |
| 10 | LEGN on Yahoo Finance (opens in a new tab) | Legend Biotech CorpSPONSORED ADS | 2.5% | $235M | 8,137,638 | Added +5.9% | $29.66 | $18.57 | -37.4% |
| 11 | COGT on Yahoo Finance (opens in a new tab) | Cogent Biosciences IncCOM | 2.0% | $194M | 5,006,104 | Trimmed -44.6% | $10.86* | $29.39 | +170.7% |
| 12 | GMAB on Yahoo Finance (opens in a new tab) | Genmab A/SSPONSORED ADS | 2.0% | $189M | 6,865,000 | Added +178.8% | $27.79 | $37.08 | +33.4% |
| 13 | BKD on Yahoo Finance (opens in a new tab) | Brookdale Sr Living IncCOM | 2.0% | $187M | 11,637,032 | Unchanged | $4.27* | $9.98 | +133.5% |
| 14 | VERA on Yahoo Finance (opens in a new tab) | Vera Therapeutics IncCL A | 1.8% | $168M | 3,916,400 | Added +5.2% | $26.91 | $27.72 | +3.0% |
| 15 | IONS on Yahoo Finance (opens in a new tab) | Ionis Pharmaceuticals IncCOM | 1.6% | $157M | 1,979,669 | Unchanged | $48.82 | $43.19 | -11.5% |
| 16 | CELC on Yahoo Finance (opens in a new tab) | Celcuity IncCOM | 1.6% | $152M | 1,451,014 | Trimmed -15.3% | $64.15 | $55.10 | -14.1% |
| 17 | BCRX on Yahoo Finance (opens in a new tab) | Biocryst Pharmaceuticals IncCOM | 1.6% | $151M | 15,096,403 | Unchanged | $7.49* | $7.78 | +3.8% |
| 18 | NAMS on Yahoo Finance (opens in a new tab) | Newamsterdam Pharma CompanyORDINARY SHARES | 1.5% | $145M | 4,264,789 | Unchanged | $20.75 | $20.05 | -3.4% |
| 19 | ACHC on Yahoo Finance (opens in a new tab) | Acadia Healthcare Company InCOM | 1.4% | $133M | 4,520,000 | Unchanged | $19.81 | $30.12 | +52.0% |
| 20 | TNGX on Yahoo Finance (opens in a new tab) | Tango Therapeutics IncCOM | 1.4% | $131M | 4,190,611 | Added +1.1% | $10.35 | $22.19 | +114.3% |
| 21 | AHCO on Yahoo Finance (opens in a new tab) | Adapthealth CorpCOMMON STOCK | 1.2% | $120M | 11,477,730 | Unchanged | $9.70* | $6.14 | -36.6% |
| 22 | PHVS on Yahoo Finance (opens in a new tab) | Pharvaris N VCOM | 1.2% | $117M | 3,376,042 | Added +8.0% | $22.11 | $27.93 | +26.3% |
| 23 | — | Celcuity IncNOTE 0.250% 8/0 | 1.2% | $114M | 100,000,000 prn | New | — | — | — |
| 24 | ARWR on Yahoo Finance (opens in a new tab) | Arrowhead Pharmaceuticals InCOM | 1.2% | $113M | 1,389,055 | Trimmed -11.7% | $34.37 | $56.27 | +63.7% |
| 25 | DNTH on Yahoo Finance (opens in a new tab) | Dianthus Therapeutics IncCOM | 1.1% | $110M | 1,125,313 | Added +10.3% | $60.67 | $69.69 | +14.9% |
| 26 | LRMR on Yahoo Finance (opens in a new tab) | Larimar Therapeutics IncCOM | 1.1% | $109M | 35,606,974 | Unchanged | $4.43* | $2.04 | -53.9% |
| 27 | MLYS on Yahoo Finance (opens in a new tab) | Mineralys Therapeutics IncCOM | 1.1% | $107M | 3,958,000 | New | $27.44 | $20.20 | -26.4% |
| 28 | — | Alignment Healthcare IncNOTE 4.250%11/1 | 1.1% | $104M | 61,000,000 prn | Unchanged | — | — | — |
| 29 | IDYA on Yahoo Finance (opens in a new tab) | Ideaya Biosciences IncCOM | 1.1% | $101M | 2,714,503 | Added +77.4% | $28.66* | $33.12 | +15.6% |
| 30 | XENE on Yahoo Finance (opens in a new tab) | Xenon Pharmaceuticals IncCOM | 1.0% | $98M | 1,615,696 | Unchanged | $41.56 | $33.55 | -19.3% |
| 31 | — | Ionis Pharmaceuticals IncNOTE 1.750% 6/1 | 1.0% | $93M | 60,000,000 prn | Unchanged | — | — | — |
| 32 | SVRA on Yahoo Finance (opens in a new tab) | Savara IncCOM | 0.9% | $84M | 13,569,000 | Unchanged | $4.51 | $4.51 | -0.2% |
| 33 | LNTH on Yahoo Finance (opens in a new tab) | Lantheus Hldgs IncCOM | 0.9% | $84M | 752,999 | Trimmed -9.1% | $58.19 | $99.87 | +71.6% |
| 34 | SNDX on Yahoo Finance (opens in a new tab) | Syndax Pharmaceuticals IncCOM | 0.9% | $83M | 3,779,900 | Unchanged | $21.73 | $12.90 | -40.6% |
| 35 | — | Zenas Biopharma IncNOTE 2.500% 4/0 | 0.8% | $80M | 67,200,000 prn | Added +3.4% | — | — | — |
| 36 | BMRN on Yahoo Finance (opens in a new tab) | Biomarin Pharmaceutical IncCOM | 0.8% | $76M | 1,332,836 | Added +56.5% | $57.03 | $54.80 | -3.9% |
| 37 | PFE on Yahoo Finance (opens in a new tab) | Pfizer IncCOM | 0.8% | $73M | 3,040,000 | Unchanged | $25.65 | $29.51 | +15.1% |
| 38 | INDV on Yahoo Finance (opens in a new tab) | Indivior Pharmaceuticals IncCOM | 0.7% | $68M | 1,648,895 | Trimmed -46.8% | $33.03 | $32.52 | -1.5% |
| 39 | BIO on Yahoo Finance (opens in a new tab) | Bio Rad Labs IncCL A | 0.7% | $66M | 226,070 | Unchanged | $343.36* | $353.91 | +3.1% |
| 40 | SPRY on Yahoo Finance (opens in a new tab) | Ars Pharmaceuticals IncCOM | 0.6% | $60M | 7,503,812 | Unchanged | $5.80* | $3.92 | -32.4% |
| 41 | STOK on Yahoo Finance (opens in a new tab) | Stoke Therapeutics IncCOM | 0.6% | $60M | 1,823,500 | Unchanged | $30.06 | $24.20 | -19.5% |
| 42 | GPCR on Yahoo Finance (opens in a new tab) | Structure Therapeutics IncSPONSORED ADS | 0.6% | $58M | 1,086,000 | Added +41.4% | $41.36* | $21.04 | -49.1% |
| 43 | NVST on Yahoo Finance (opens in a new tab) | Envista Holdings CorporationCOM | 0.6% | $58M | 2,210,100 | Unchanged | $19.44 | $22.98 | +18.2% |
| 44 | INSP on Yahoo Finance (opens in a new tab) | Inspire Med Sys IncCOM | 0.6% | $58M | 1,296,862 | Trimmed -52.0% | $88.73 | $69.19 | -22.0% |
| 45 | CDNA on Yahoo Finance (opens in a new tab) | Caredx IncCOM | 0.6% | $57M | 1,997,618 | Trimmed -8.8% | $14.26 | $63.52 | +345.6% |
| 46 | BSX on Yahoo Finance (opens in a new tab) | Boston Scientific CorpCOM | 0.6% | $56M | 1,315,000 | New | $54.30 | $44.06 | -18.8% |
| 47 | BLTE on Yahoo Finance (opens in a new tab) | Belite Bio IncSPONSORED ADS | 0.6% | $55M | 357,199 | Added +17.5% | $133.40 | $143.41 | +7.5% |
| 48 | PBLS on Yahoo Finance (opens in a new tab) | Parabilis Medicines IncCOM | 0.5% | $51M | 1,880,704 | New | $27.62 | $23.77 | -13.9% |
| 49 | CERT on Yahoo Finance (opens in a new tab) | Certara IncCOM | 0.5% | $49M | 7,512,928 | Trimmed -3.8% | $11.38 | $9.24 | -18.8% |
| 50 | IRON on Yahoo Finance (opens in a new tab) | Disc Medicine IncCOM | 0.5% | $48M | 657,000 | Unchanged | $53.72* | $56.21 | +4.6% |
| 51 | — | Livanova PLCNOTE 2.500% 3/1 | 0.5% | $46M | 34,280,000 prn | Unchanged | — | — | — |
| 52 | BBOT on Yahoo Finance (opens in a new tab) | Bridgebio Oncology TherapeutCOM NEW | 0.4% | $37M | 4,885,446 | Unchanged | $10.42 | $2.82 | -72.9% |
| 53 | TYRA on Yahoo Finance (opens in a new tab) | Tyra Biosciences IncCOM | 0.3% | $32M | 1,017,000 | Added +85.2% | $32.70 | $18.47 | -43.5% |
| 54 | MNPR on Yahoo Finance (opens in a new tab) | Monopar Therapeutics IncCOM NEW | 0.3% | $30M | 323,745 | Unchanged | $53.36 | $69.54 | +30.3% |
| 55 | SION on Yahoo Finance (opens in a new tab) | Sionna Therapeutics IncCOM | 0.3% | $30M | 680,916 | Trimmed -29.8% | $15.59 | $3.88 | -75.1% |
| 56 | — | Immunocore Hldgs PLCNOTE 2.500% 2/0 | 0.3% | $27M | 30,000,000 prn | Unchanged | — | — | — |
| 57 | AVLN on Yahoo Finance (opens in a new tab) | Avalyn Pharmaceuticals IncCOM SHS | 0.3% | $24M | 731,000 | New | $28.86 | $23.81 | -17.5% |
| 58 | FHTX on Yahoo Finance (opens in a new tab) | Foghorn Therapeutics IncCOM | 0.2% | $21M | 4,394,367 | Unchanged | $5.97 | $1.85 | -69.0% |
| 59 | BBNX on Yahoo Finance (opens in a new tab) | Beta Bionics IncCOM | 0.2% | $21M | 1,324,000 | Unchanged | $17.11 | $16.84 | -1.6% |
| 60 | ALNY on Yahoo Finance (opens in a new tab) | Alnylam Pharmaceuticals IncCOM | 0.2% | $20M | 67,935 | Unchanged | $175.80 | $233.42 | +32.8% |
| 61 | DRUG on Yahoo Finance (opens in a new tab) | Bright Minds Biosciences IncCOM NEW | 0.2% | $20M | 283,000 | Unchanged | $80.49 | $51.61 | -35.9% |
| 62 | ODTX on Yahoo Finance (opens in a new tab) | Odyssey Therapeutics IncCOMMON STOCK | 0.2% | $20M | 1,046,139 | New | $17.54 | $17.07 | -2.7% |
| 63 | STLN on Yahoo Finance (opens in a new tab) | The Oncology Institute IncCOM | 0.2% | $18M | 3,360,052 | Unchanged | $1.45* | $6.72 | +363.9% |
| 64 | KYTX on Yahoo Finance (opens in a new tab) | Kyverna Therapeutics IncCOM | 0.2% | $18M | 2,000,000 | Unchanged | $7.42 | $5.76 | -22.4% |
| 65 | ALMR on Yahoo Finance (opens in a new tab) | Alamar Biosciences IncCOMMON STOCK | 0.2% | $16M | 600,000 | New | $22.63 | $25.39 | +12.2% |
| 66 | CHE on Yahoo Finance (opens in a new tab) | Chemed Corp NewCOM | 0.1% | $14M | 30,000 | New | $419.54 | $511.54 | +21.9% |
| 67 | SGP on Yahoo Finance (opens in a new tab) | Spyglass Pharma IncCOM SHS | 0.1% | $12M | 550,000 | Unchanged | $26.90 | $24.58 | -8.6% |
| 68 | — | Neogenomics IncNOTE 0.250% 1/1 | 0.1% | $12M | 13,040,000 prn | Trimmed -82.1% | — | — | — |
| 69 | ADAG on Yahoo Finance (opens in a new tab) | Adagene IncADS | 0.1% | $11M | 2,666,666 | New | $3.76 | $2.16 | -42.6% |
| 70 | COAG on Yahoo Finance (opens in a new tab) | Hemab Therapeutics Hldgs IncCOM SHS | 0.1% | $10M | 275,000 | New | $27.59 | $30.25 | +9.6% |
| 71 | MOBI on Yahoo Finance (opens in a new tab) | Mobia Med IncCOMMON STOCK | 0.1% | $9M | 670,752 | New | $12.95 | $8.12 | -37.3% |
| 72 | EMBC on Yahoo Finance (opens in a new tab) | Embecta CorpCOMMON STOCK | 0.1% | $8M | 2,534,961 | Unchanged | $14.35 | $6.33 | -55.9% |
| 73 | VCYT on Yahoo Finance (opens in a new tab) | Veracyte IncCOM | 0.1% | $6M | 101,000 | Trimmed -86.1% | $28.92 | $43.35 | +49.9% |
| 74 | ANNX on Yahoo Finance (opens in a new tab) | Annexon IncCOM | 0.0% | $3M | 583,913 | Unchanged | $2.45* | $3.38 | +38.4% |
| 75 | ALEC on Yahoo Finance (opens in a new tab) | Alector IncCOM | 0.0% | $2M | 1,055,192 | Unchanged | $6.06* | $1.90 | -68.6% |
| 76 | NAMSW on Yahoo Finance (opens in a new tab) | Newamsterdam Pharma Company*W EXP 99/99/999 | 0.0% | $2M | 92,787 | Unchanged | $1.84* | $8.82 | +379.3% |
| 77 | EW on Yahoo Finance (opens in a new tab) | Edwards Lifesciences CorpCOM | 0.0% | $1M | 13,702 | Unchanged | $80.24 | $86.28 | +7.5% |
| 78 | MIRM on Yahoo Finance (opens in a new tab) | Mirum Pharmaceuticals IncCOM | 0.0% | $706K | 6,027 | New | $100.40 | $80.24 | -20.1% |
| 79 | HUM on Yahoo Finance (opens in a new tab) | Humana IncCOM | 0.0% | $364K | 917 | Unchanged | $261.64 | $417.60 | +59.6% |
| 80 | STLNW on Yahoo Finance (opens in a new tab) | The Oncology Institute Inc*W EXP 99/99/999 | 0.0% | $51K | 1,250,000 | Unchanged | — | $0.03 | — |
| 81 | PMVP on Yahoo Finance (opens in a new tab) | Pmv Pharmaceuticals IncCOM | 0.0% | $12K | 8,790 | Unchanged | $0.98 | $1.23 | +25.4% |
| 82 | SRZN on Yahoo Finance (opens in a new tab) | Surrozen Inc*W EXP 08/01/203 | 0.0% | $3K | 166,666 | Unchanged | $7.33* | $23.36 | +218.9% |
Sold out since Q1 2026
- —Mirum Pharmaceuticals Inc$209M at Q1 2026
- —Catalyst Pharmaceuticals Inc$98M at Q1 2026
- NBIX on Yahoo Finance (opens in a new tab)Neurocrine Biosciences Inc$80M at Q1 2026
- —Day One Biopharmaceuticals I$80M at Q1 2026
- —Enhabit Inc$67M at Q1 2026
- KYMR on Yahoo Finance (opens in a new tab)Kymera Therapeutics Inc$47M at Q1 2026
- CMPX on Yahoo Finance (opens in a new tab)Compass Therapeutics Inc$19M at Q1 2026
- TSHA on Yahoo Finance (opens in a new tab)Taysha Gene Therapies Inc$12M at Q1 2026
- CGEM on Yahoo Finance (opens in a new tab)Cullinan Therapeutics Inc$5M at Q1 2026
- —Biomx Inc$493K at Q1 2026
- MANE on Yahoo Finance (opens in a new tab)Veradermics Inc$316K at Q1 2026
- QSI on Yahoo Finance (opens in a new tab)Quantum Si Inc$36K at Q1 2026
- MYGN on Yahoo Finance (opens in a new tab)Myriad Genetics Inc$2K at Q1 2026
Estimated, from reported holdings
Quarter by quarter
High-conviction buys (new positions at 3% or more of the portfolio) since Q3 2023: 0. Of 0 with six months of history, — beat the S&P 500 from the filing date.
Source: SEC Form 13F-HR 0001213900-26-089991, compared with the Q1 2026 report. 0 option rows are excluded from weights. Tickers map from CUSIP via OpenFIGI. Estimated returns weight each position’s next-quarter total return (Yahoo Finance adjusted closes) by its quarter-end value and assume no trades. Estimated cost averages daily adjusted closes in each quarter the share count rose, from Q3 2023 onward (* = held at the start of our data). Price is the latest close.
Important information
Form 13F data is delayed. Managers have up to 45 days after each calendar quarter to file, so holdings shown may have changed materially since the report date. 13F reports cover long positions in US-listed equities and certain other securities only; they exclude short positions, most non-US holdings, cash, bonds and private investments, and managers may request confidential treatment for some positions. Options rows are listed in filings but are not counted in the holdings and weights shown here.
Estimated holdings returns, estimated cost and high-conviction results are hypothetical calculations from quarter-end holdings and public prices, assuming no trades between reports. They are not the actual returns or costs of any fund or manager and do not reflect fees, trading, leverage, shorts or cash. Biographies are drawn from cited public sources. This page is for information only and is not individualized investment advice or a recommendation to buy or sell any security. Gulfstream Capital and its clients may hold positions in securities shown.